About lyra therapeutics inc - LYRA
Lyra Therapeutics, Inc. is a clinical-stage therapeutics company. It develops novel integrated drug and delivery solutions for the localized treatment of patients with ear, nose and throat, or ENT, diseases. The firms proprietary XTreo deliver medicines. The company was founded by Carmichael S. Roberts, George M. Whitesides, and Robert S. Langer in November 2005 and is headquartered in Watertown, MA.
LYRA At a Glance
Lyra Therapeutics, Inc.
480 Arsenal Way
Watertown, Massachusetts 02472
| Phone | 1-617-393-4600 | Revenue | 398.00K | |
| Industry | Pharmaceuticals: Major | Net Income | -28,919,000.00 | |
| Sector | Health Technology | Employees | 27 | |
| Fiscal Year-end | 12 / 2026 | |||
| View SEC Filings |
LYRA Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | 12.022 |
| Price to Book Ratio | N/A |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | -0.658 |
| Enterprise Value to Sales | 48.117 |
| Total Debt to Enterprise Value | 1.58 |
LYRA Efficiency
| Revenue/Employee | 14,740.741 |
| Income Per Employee | -1,071,074.074 |
| Receivables Turnover | N/A |
| Total Asset Turnover | 0.008 |
LYRA Liquidity
| Current Ratio | 1.709 |
| Quick Ratio | 1.709 |
| Cash Ratio | 1.669 |
LYRA Profitability
| Gross Margin | -15.327 |
| Operating Margin | -7,425.377 |
| Pretax Margin | -7,263.317 |
| Net Margin | -7,266.08 |
| Return on Assets | -56.453 |
| Return on Equity | -6,594.983 |
| Return on Total Capital | -147.984 |
| Return on Invested Capital | -102.229 |
LYRA Capital Structure
| Total Debt to Total Equity | N/A |
| Total Debt to Total Capital | 154.841 |
| Total Debt to Total Assets | 83.801 |
| Long-Term Debt to Equity | N/A |
| Long-Term Debt to Total Capital | 130.186 |